Urolithins and their possible implications for diabetic kidney

Full item record

dc.contributor.authorKotewicz, Milena
dc.contributor.authorLewko, Barbara
dc.contributor.organizationDepartment of Pharmaceutical Pathophysiology, Medical University of Gdańsk, Polanden
dc.date.accessioned2022-07-14T13:02:44Z
dc.date.available2022-07-14T13:02:44Z
dc.date.issued2022-02-21
dc.description.abstractThe increasing prevalence of diabetic kidney disease (DKD), a common complication of type 1 and type 2 diabetes, is becoming a leading risk factor of developing end stage renal disease (ESRD). The multiple mechanisms involved in renal tissue damage are a challenge for effective targeted therapy. Urolithins are metabolites generated by gut microbiota upon dietary intake of plant-derived ellagitannins. Multidirectional effects of these compounds include their anti-inflammatory, antioxidant, anti-proliferatory, anti-migratory and antiglycative properties that are mediated by modulation of signaling pathways and gene expression. Biochemical properties of urolithins indicate their capacity to regulate numerous mechanisms responsible for developing the hyperglycemia-induced tissue injury. The potentially beneficial effects of urolithins on podocytes, the most vulnerable renal cells should be particularly considered. The purpose of this review is to provide the evidence from the in vivo and in vitro studies showing that urolithin-based therapy could be a useful tool for protecting the kidneys from damage in diabetes.en
dc.identifier.citationKotewicz M, Lewko B. Urolithins and their possible implications for diabetic kidney. Eur J Transl Clin Med. 2022;5(1):53-63. DOI: 10.31373/ejtcm/137918en
dc.identifier.doi10.31373/ejtcm/137918
dc.identifier.issn2657-3156
dc.identifier.urihttps://open.icm.edu.pl/handle/123456789/21480
dc.language.isoen
dc.publisherMedical University of Gdańsken
dc.rightsUznanie autorstwa-Na tych samych warunkach 4.0 Międzynarodowe*
dc.rights.urihttp://creativecommons.org/licenses/by-sa/4.0/*
dc.subjecturolithinsen
dc.subjectdiabetesen
dc.subjectkidneyen
dc.subjectpodocytesen
dc.titleUrolithins and their possible implications for diabetic kidneyen
dc.typearticleen
Files for this record
Original bundle
Now showing 1 - 1 of 1
Name: EJTCM_2022_5_1_Kotewicz.pdf
Size: 775.12 KB
Format: Adobe Portable Document Format
Description:
License files
Name: license.txt
Size: 452 B
Format: Plain Text
Description:
Name: license_rdf
Size: 1.01 KB
Format: RDF serialized in XML
Description:
Belongs to collection